MEA Pharmacogenetic Testing Market - Industry Trends and Forecast to 2033
The Middle East and Africa pharmacogenetic testing market is expected to reach USD 240.34 million by 2030 from USD 159.73 million in 2022, growing at a CAGR of 5.4% during the forecast period of 2023 to 2030.
Market SegmentationMiddle East and Africa Pharmacogenetic Testing Market, By Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 AND VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX AND MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services), Country (South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and rest of Middle East and Africa) - Industry Trends and Forecast to 2030
Overview of Global Pharmacogenetic Testing Market Dynamics
Driver
• Rapid technological advancement and miniaturization
Restrain
• Environment and health concerns
Opportunity
• Rising research and development and innovative technologies
Market Players
Some of the major market players operating in the Middle East and Africa pharmacogenetic testing market are: • Thermo Fisher Scientific
• Illumina, Inc
• QIAGEN
• Sonic Healthcare
• BGI